Literature DB >> 24011067

FGF21 mimetic shows therapeutic promise.

Marc L Reitman1.   

Abstract

FGF21 is a protein with multiple metabolic actions, currently a bright star beckoning on the metabolic disease therapeutic horizon. Gaich et al. (2013) present the first clinical efficacy trial for an FGF21 mimetic, finding robust lipid-lowering effects, some reduction in body weight, but surprisingly modest effects on glucose homeostasis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24011067      PMCID： PMC3789140          DOI： 10.1016/j.cmet.2013.08.014

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  9 in total

Review 1.  Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

Authors:  Matthew J Potthoff; Steven A Kliewer; David J Mangelsdorf
Journal:  Genes Dev       Date:  2012-02-02       Impact factor: 11.361

2.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

Authors:  Wei Wei; Paul A Dutchak; Xunde Wang; Xunshan Ding; Xueqian Wang; Angie L Bookout; Regina Goetz; Moosa Mohammadi; Robert D Gerard; Paul C Dechow; David J Mangelsdorf; Steven A Kliewer; Yihong Wan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

3.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

Authors:  Gregory Gaich; Jenny Y Chien; Haoda Fu; Leonard C Glass; Mark A Deeg; William L Holland; Alexei Kharitonenkov; Thomas Bumol; Holger K Schilske; David E Moller
Journal:  Cell Metab       Date:  2013-09-03       Impact factor: 27.287

4.  Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Authors:  Ai-Luen Wu; Ganesh Kolumam; Scott Stawicki; Yongmei Chen; Jun Li; Jose Zavala-Solorio; Khanhky Phamluong; Bo Feng; Li Li; Scot Marsters; Lance Kates; Nicholas van Bruggen; Maya Leabman; Anne Wong; David West; Howard Stern; Elizabeth Luis; Hok Seon Kim; Daniel Yansura; Andrew S Peterson; Ellen Filvaroff; Yan Wu; Junichiro Sonoda
Journal:  Sci Transl Med       Date:  2011-12-14       Impact factor: 17.956

5.  Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Authors:  Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2013-05-29       Impact factor: 7.422

6.  An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.

Authors:  William L Holland; Andrew C Adams; Joseph T Brozinick; Hai H Bui; Yukiko Miyauchi; Christine M Kusminski; Steven M Bauer; Mark Wade; Esha Singhal; Christine C Cheng; Katherine Volk; Ming-Shang Kuo; Ruth Gordillo; Alexei Kharitonenkov; Philipp E Scherer
Journal:  Cell Metab       Date:  2013-05-07       Impact factor: 27.287

7.  Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.

Authors:  Zhuofeng Lin; Haishan Tian; Karen S L Lam; Shaoqiang Lin; Ruby C L Hoo; Morichika Konishi; Nobuyuki Itoh; Yu Wang; Stefan R Bornstein; Aimin Xu; Xiaokun Li
Journal:  Cell Metab       Date:  2013-05-07       Impact factor: 27.287

8.  Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Authors:  Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

9.  Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.

Authors:  Alexei Kharitonenkov; John M Beals; Radmila Micanovic; Beth A Strifler; Radhakrishnan Rathnachalam; Victor J Wroblewski; Shun Li; Anja Koester; Amy M Ford; Tamer Coskun; James D Dunbar; Christine C Cheng; Christopher C Frye; Thomas F Bumol; David E Moller
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240
  9 in total
  15 in total

1.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

2.  Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

Authors:  Mohammad Zarei; Eugènia Pujol; Tania Quesada-López; Francesc Villarroya; Emma Barroso; Santiago Vázquez; Javier Pizarro-Delgado; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  Br J Pharmacol       Date:  2019-05-23       Impact factor: 8.739

3.  Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution.

Authors:  Yun-Hee Youm; Tamas L Horvath; David J Mangelsdorf; Steven A Kliewer; Vishwa Deep Dixit
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

4.  Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Authors:  Qi Cheng; Nishank Shah; Angelika Bröer; Stephen Fairweather; Yang Jiang; Dieter Schmoll; Ben Corry; Stefan Bröer
Journal:  Br J Pharmacol       Date:  2017-02-14       Impact factor: 8.739

5.  FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway.

Authors:  Xiaolong Lin; Guohua Li; Xinglan He; Xiaofeng Ma; Kai Zhang; Hai Zhang; Gaofeng Zeng; Zuo Wang
Journal:  Mol Cell Biochem       Date:  2014-04-04       Impact factor: 3.396

Review 6.  Nuclear receptors and metabolism: from feast to famine.

Authors:  Suk-Hyun Hong; Maryam Ahmadian; Ruth T Yu; Annette R Atkins; Michael Downes; Ronald M Evans
Journal:  Diabetologia       Date:  2014-03-12       Impact factor: 10.122

7.  Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes.

Authors:  Darwin V Lee; Dongmei Li; Qingyun Yan; Yimin Zhu; Bryan Goodwin; Roberto Calle; Martin B Brenner; Saswata Talukdar
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

8.  Induction of peroxisomes by butyrate-producing probiotics.

Authors:  Huachun Weng; Kosuke Endo; Jiawei Li; Naoko Kito; Naoharu Iwai
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.

Authors:  Yan Weng; Jeffrey R Chabot; Barbara Bernardo; Qingyun Yan; Yimin Zhu; Martin B Brenner; Chandra Vage; Alison Logan; Roberto Calle; Saswata Talukdar
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

10.  Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice.

Authors:  Xin-Hua Liu; Zachary A Graham; Lauren Harlow; Jiangping Pan; Daniella Azulai; William A Bauman; Joshua Yarrow; Christopher P Cardozo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-11       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.